Form 4: Insmed COO Sells Shares Under 10b5-1 Plan

Insmed Inc. Chief Operating Officer Roger Adsett reported the sale of company stock totaling over 78,000 shares, executed under a pre-arranged trading plan.

Summary

• Roger Adsett, Chief Operating Officer of Insmed Inc. (INSM), reported transactions involving the sale of common stock on April 1, 2026.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on December 3, 2025.
• A total of 88,060 shares were acquired at a price of $14.56, with 6,715 shares sold at a weighted average price of $163.18, 19,001 shares sold at a weighted average price of $164.11, and 62,344 shares sold at a weighted average price of $164.95.
• Following these transactions, Adsett beneficially owns 169,154 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to the significant sale of shares by a top executive, even though it was conducted under a pre-arranged plan.

Positives

• The transactions were executed under a 10b5-1 plan, indicating pre-planned and potentially non-insider trading related sales.
• The acquisition of 88,060 shares at $14.56 suggests a potential stock purchase or option exercise at a favorable price.
• The reporting person still beneficially owns a significant number of shares (169,154) after the reported sales.

Negatives

• A substantial number of shares (78,060) were sold by a key executive.
• The sale prices ($163.18 to $164.95) are significantly higher than the acquisition price ($14.56), indicating a considerable profit for the reporting person.

Risks

• The sale of a large number of shares by a Chief Operating Officer could be interpreted negatively by the market, potentially signaling a lack of confidence in future stock performance, despite being executed under a 10b5-1 plan.
• The weighted average sale prices indicate that the shares were sold at a premium, which could be a point of concern if the stock price subsequently declines.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The future outlook for Insmed Inc. would be derived from other company disclosures.

Management Comments

• The transactions were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request for the weighted average sales prices.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for executives and directors, often related to pre-scheduled sales plans (10b5-1) designed to diversify holdings or meet financial obligations. While these plans are intended to mitigate insider trading concerns, significant sales by C-suite executives can still influence market perception.

Stakeholder Impact

• Shareholders: May view the sale of a significant number of shares by the COO with caution, potentially impacting short-term stock price sentiment.
• Employees: May be influenced by executive trading activity, though the 10b5-1 plan mitigates direct insider trading concerns.
• Management: The COO's actions under the 10b5-1 plan are a standard practice for managing personal finances while adhering to regulatory requirements.

Next Steps

• The reporting person may continue to execute transactions under the existing 10b5-1 plan.
• The company may provide further financial or strategic updates in subsequent filings.

Key Dates

Recommendation

This Form 4 filing reports routine stock transactions by an executive under a 10b5-1 plan. While the sale of a significant number of shares could be a short-term negative signal, the pre-planned nature of the transaction and the continued beneficial ownership of a substantial amount of stock suggest it is not indicative of a fundamental change in the company's outlook. Therefore, a 'hold' recommendation is appropriate, pending further information on the company's performance and strategy.

Keywords

Form 4, SEC Filing, Insmed Inc, INSM, Roger Adsett, Stock Sale, 10b5-1 Plan, Insider Trading, Beneficial Ownership, Chief Operating Officer